Elderly patients > 65 years of age with acute myeloid leukemia and normal karyotype benefit from intensive therapeutic programs

Am J Hematol. 2016 Jun;91(6):E302-3. doi: 10.1002/ajh.24345. Epub 2016 Apr 13.

Authors

Massimo Bernardi¹, Matteo Carrabba¹, Carlo Messina¹, Raffaella Milani^{1

2}, Elisa Sala^{1

2}, Francesca Pavesi^{1

2}, Bernhard Gentner^{1

2}, Jacopo Peccatori^{1

2}, Andrea Assanelli^{1

2}, Sarah Marktel^{1

2}, Consuelo Corti^{1

2}, Alessandra Forcina^{1

2}, Luca Vago^{1

2}, Fabio Ciceri^{1

2}

Affiliations

¹ Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy.
² University Vita-Salute, Milan, 20132, Italy.

PMID: 26928240
DOI: 10.1002/ajh.24345

No abstract available

Publication types

Letter

MeSH terms

Age Factors
Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Combined Modality Therapy
Female
Hematopoietic Stem Cell Transplantation / methods
Humans
Karyotype*
Leukemia, Myeloid, Acute / genetics*
Leukemia, Myeloid, Acute / mortality
Leukemia, Myeloid, Acute / therapy*
Male
Middle Aged
Treatment Outcome